Stem cell research market to 2017 has strong pipeline, but high unmet needs in chronic diseases

Strategic partnerships between pharmaceutical companies and stem cell research companies have been given a boost in stem cell R&D, according to a new report from GBI Research. Almost 90% of the drugs in clinical trials fail due to factors such as lack of effectiveness and adverse side effects of the drug.

Animal or tumor cells are mostly being used and this leads to jury-rigged tests. Hence, all major pharmaceutical companies look forward to new technologies that increase the possibility to launch new therapies in the market place. At present, there has been a spur in investments from pharmaceutical companies into stem cell research through strategic partnerships with stem cell research companies.

Major pharmaceutical companies have planned and aligned their objectives to enter the stem cell market in the next three to five years, although there have been few strategic partnerships already between pharmaceutical companies and stem cell research based companies. Pharmaceutical companies are also keen to explore various methods where stem cells could be utilized in the drug discovery process that would accelerate the discovery of novel drug molecules.